/biz/ - Business & Finance

weigh in on syn, nlnk and ptn.
Nlnk has a phase 3 trial coming up of some drug that did pretty well for its phase 2 (was the reason nlnk spiked from like 7 to 19 bucks earlier in the month).
Syn has a good partnership going and is pushing their drug syn 004 to markets.
Ptn are pretty much doing the same thing as syn but with a different drug and different partner.
I was also looking at TEUM because they have a good revanue backlog and a bunch of recent contracts.